Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$35.97 USD

35.97
6,376,897

-0.94 (-2.55%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $35.97 0.00 (0.00%) 5:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (50 out of 252)

Industry: Medical - Products

Better trading starts here.

Zacks News

McKesson (MCK) Beats Q2 Earnings, Misses Revenue Estimates

McKesson's (MCK) Q2 results benefit from solid performance in the Medical-Surgical Solutions segment.

What's in Store for Weight Watchers' (WTW) Q3 Earnings?

Weight Watchers (WTW) likely to see soft segmental revenues in Q3; EPS guidance raised.

Align Technology (ALGN) Beats on Earnings and Revenues in Q3

Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q3.

Will Robust ICL Sales Aid STAAR Surgical (STAA) Q3 Earnings?

STAAR Surgical (STAA) is expected to pitch in a solid top-line contribution with its Implantable Collamer Lens (ICL) consisting of the EVO Visian ICL product line.

Will Amedisys' (AMED) Q3 Earnings Reflect Overall Gain?

Amedisys' (AMED) Q3 is anticipated to benefit from a strong uptick across all its three business lines consisting of Home Health, Hospice and Personal Care.

LabCorp (LH) Q3 Earnings Lag Estimates, Guidance Tweaked

Within LabCorp (LH) Diagnostics business the disposition of certain businesses and the implementation of the Protecting Access to Medicare Act (PAMA) dented growth.

Thermo Fisher (TMO) Beats on Q3 Earnings, Ups '18 Guidance

Thermo Fisher (TMO) raises its 2018 revenue view, banking on a solid third-quarter operational performance, partially offset by a less favorable foreign exchange.

Edwards Lifesciences (EW) Earnings Beat, Revenues Miss in Q3

Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q3.

Baxter International (BAX) Q3 Earnings Preview: Here's What to Look Out For

Baxter (BAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Illumina (ILMN) Beats Earnings and Revenue Estimates in Q3

Illumina (ILMN) gains on strong consumables growth across its sequencing portfolio with strength in all throughput categories and microarray business in Q3.

Boston Scientific (BSX) Beats on Q3 Earnings, Misses Revenues

Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q3.

Varian (VAR) Misses Earnings, Beats Revenue Estimates in Q4

Varian's (VAR) Q4 results benefit from strong growth in Oncology Systems. Also, solid guidance boosts investors' optimism.

Can Medication Delivery Unit Aid Baxter's (BAX) Q3 Earnings?

Baxter (BAX) likely to gain from strong Medication Delivery revenues; guidance for 2018 raised.

Will Healthcare Arm Drive BioTelemetry's (BEAT) Q3 Earnings?

Product launches, synergies from LifeWatch acquisition and favorable payor mix are expected to have worked in favor of BioTelemetry's (BEAT) Healthcare arm in Q3.

Quest Diagnostics (DGX) Q3 Earnings Meet, Guidance Tweaked

Quest Diagnostics (DGX) gains on successful execution of its strategy of accelerating growth in Q3.

PetMed (PETS) Q2 Earnings Grow Y/Y, Reorder Sales Solid

PetMed's (PETS) reorder sales growth solid in Q2. Increased online sales buoy optimism.

What's in Store for Medpace Holdings (MEDP) in Q3 Earnings?

Medpace Holdings' (MEDP) revenue growth in Q3 to be driven by strength in oncology, cardiometabolic, antiviral and anti-infectious diseases solutions.

Will Global Industrial Unit Boost Ecolab's (ECL) Q3 Earnings?

Solid performance in the Global Industrial segment to drive Ecolab's (ECL) Q3 results.

Will Core MedSurg Segment Aid Stryker's (SYK) Q3 Earnings?

Stryker (SYK) is likely to gain from strong segmental performance in Q3; softness anticipated in Spine business.

What's in Store for Zimmer Biomet (ZBH) This Earnings Season?

Focusing on areas like quality correction, supply recovery and product introductions, Zimmer Biomet (ZBH) is expected to see robust top-line numbers at S.E.T. arm in Q3.

Medidata (MDSO) Tops Earnings & Revenue Estimates in Q3

Strong performance in the Subscription revenues segment drives Medidata???s (MDSO) results in Q3. Professional services also posted steady growth.

Will Core Business Units Aid McKesson's (MCK) Q2 Earnings?

McKesson (MCK) is expected to gain from strong segmental performances in Q2 of fiscal 2019.

Has Baxter International (BAX) Outpaced Other Medical Stocks This Year?

Is (BAX) Outperforming Other Medical Stocks This Year?

BAX vs. BSX: Which Stock Should Value Investors Buy Now?

BAX vs. BSX: Which Stock Is the Better Value Option?

Mallinckrodt (MNK) Gets $26 Million as Funding From BARDA

Mallinckrodt (MNK) gets $26 million for additional funding from BARDA for pediatric studies of StrataGraft skin tissue in thermal burns.